Livforsakringsbolaget Skandia, Omsesidigt Vertex Pharmaceuticals Inc Transaction History
Livforsakringsbolaget Skandia, Omsesidigt
- $1.73 Billion
- Q1 2025
A detailed history of Livforsakringsbolaget Skandia, Omsesidigt transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Livforsakringsbolaget Skandia, Omsesidigt holds 27,620 shares of VRTX stock, worth $13.2 Million. This represents 0.77% of its overall portfolio holdings.
Number of Shares
27,620
Previous 27,820
0.72%
Holding current value
$13.2 Million
Previous $11.2 Million
19.52%
% of portfolio
0.77%
Previous 0.6%
Shares
25 transactions
Others Institutions Holding VRTX
# of Institutions
1,784Shares Held
224MCall Options Held
1.63MPut Options Held
1.47M-
Capital World Investors Los Angeles, CA28.3MShares$13.5 Billion1.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.3MShares$11.1 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.2 Billion0.23% of portfolio
-
State Street Corp Boston, MA12MShares$5.72 Billion0.2% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.4MShares$4.98 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $123B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...